Outlook Therapeutics, Inc. (NASDAQ:OTLK) was founded in January 2010, formerly known as Oncobiologics, Inc. (formerly NASDAQ:ONS), changed its current name in December 2018, and is headquartered in Cranbury, New Jersey, USA , With 56 full-time employees (12/31/2018), is a clinical-stage biopharmaceutical company, focusing on the development and commercialization of monoclonal antibodies for various ophthalmic indications.
Outlook Therapeutics, Inc. (OTLK):
Outlook Therapeutics’ current focus of research is on the technically challenging and commercially attractive monoclonal antibody (mAb), immunology and oncology disease fields. Outlook Therapeutics’ strategy is to develop these biosimilars cost-effectively, which is the foundation of its success, and the company believes to make itself a leading biosimilar company.
Outlook Therapeutics uses its team’s expertise in the biopharmaceutical field to establish its fully integrated internal development and manufacturing capabilities, which is its BioSymphony™ Platform. The Outlook Therapeutics platform solves many complex technical and regulatory challenges in the development and commercialization of monoclonal antibody biosimilars, with the goal of providing significant flexibility.
Outlook Therapeutics’ first product candidate-ONS-5010, a patented ophthalmic bevacizumab product candidate, is the first clinical trial stage product for the treatment of wet age-related macular degeneration and other retinal diseases.
Outlook Therapeutics and MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, SA de CV; BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. have signed a cooperation agreement.
Outlook Therapeutics, Inc. (OTLK) investment:
Oncobiologics, Inc. submitted its IPO prospectus on 1/15/2016, and was listed on NASDAQ together with Cancer Prevention Pharmaceuticals (CPP), Spring Bank Pharmaceuticals (SBPH) and Intellia Therapeutics (NTLA) on May 6, 2016 . The price is 6.00 US dollars, 5 million shares are issued, 30 million US dollars are raised, and the stock code is ONSIU (formerly ONS, later changed to ONSIU).
On March 8, 2019, Outlook Therapeutics shares 8 shares into 1 share.